有关科创板科创成长层！上市公司掌门人、保荐机构、参投机构最新发声！

Core Insights - Three unprofitable companies, Wuhan Heyuan Biotechnology Co., Ltd., Xi'an Yiswei Material Technology Co., Ltd., and Guangzhou Bibete Pharmaceutical Co., Ltd., have officially listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone for the board's growth layer [1] Company Perspectives - Heyuan Biotechnology emphasizes the importance of long-term capital and patient investors, stating that their listing accelerates industrialization and enhances competitive capabilities in the biopharmaceutical sector [2] - Xi'an Yiswei highlights the role of recent policy reforms in facilitating access to capital markets, allowing for accelerated technology transformation and improved industrialization capabilities [3] - Both companies express a commitment to continuous technological innovation and adherence to regulatory requirements, aiming to enhance product quality and management efficiency [4] Sponsor Institution Insights - The sponsor institution, Guotai Junan, underscores the significance of the Sci-Tech Innovation Board's growth layer for both companies and the industry, noting the high R&D investment and associated risks, but also the substantial benefits upon successful product development [5] - The board is designed to support high-tech companies with tailored listing standards and regulatory logic, reflecting a commitment to fostering high-quality economic development [6] Investor Perspectives - Investment institutions involved with the newly listed companies express that the Sci-Tech Innovation Board's policies have broadened exit channels and improved investment precision, thereby enhancing capital circulation efficiency [7] - The reforms are seen as a solution to the financing challenges faced by unprofitable tech companies, allowing for a positive cycle of technological breakthroughs and capital reinvestment [8]